[
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals (NasdaqGS:VRTX) Secures EU Approval for New CF Treatment Access",
    "summary": "Vertex Pharmaceuticals (NasdaqGS:VRTX) recently received approval from the European Commission for ALYFTREK, enhancing its reach in European markets with new reimbursement agreements in Ireland and Denmark. These developments likely contributed positively to its stock price, which saw a 2% increase over the past month. However, the overall market trends, such as the S&P 500's rise fueled by tech sector gains, also played a role. While Vertex's advancements in cystic fibrosis treatment...",
    "url": "https://finnhub.io/api/news?id=560808d9d2ee82b9dd7f015adbf504354cf326c99e3a9b84b13b9b9fee7c5275",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751477248,
      "headline": "Vertex Pharmaceuticals (NasdaqGS:VRTX) Secures EU Approval for New CF Treatment Access",
      "id": 135735904,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex Pharmaceuticals (NasdaqGS:VRTX) recently received approval from the European Commission for ALYFTREK, enhancing its reach in European markets with new reimbursement agreements in Ireland and Denmark. These developments likely contributed positively to its stock price, which saw a 2% increase over the past month. However, the overall market trends, such as the S&P 500's rise fueled by tech sector gains, also played a role. While Vertex's advancements in cystic fibrosis treatment...",
      "url": "https://finnhub.io/api/news?id=560808d9d2ee82b9dd7f015adbf504354cf326c99e3a9b84b13b9b9fee7c5275"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
    "summary": "Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=12c156c3408fbc4d3580a5e3cf5965f433e5c0f4addddcb92995284d019afa0c",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751474280,
      "headline": "Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
      "id": 135732753,
      "image": "",
      "related": "VRTX",
      "source": "MarketWatch",
      "summary": "Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=12c156c3408fbc4d3580a5e3cf5965f433e5c0f4addddcb92995284d019afa0c"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know",
    "summary": "Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=382c9351ddaa917752bf1fb4391cf3c6e3499dcc838e88374d22d6618b80bc8c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751461203,
      "headline": "Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know",
      "id": 135714210,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=382c9351ddaa917752bf1fb4391cf3c6e3499dcc838e88374d22d6618b80bc8c"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Gets EU Nod for New Cystic Fibrosis Drug Alyftrek",
    "summary": "VRTX secures EU approval for Alyftrek, a next-in-class triple combination regimen for treating people with CF aged six years and older.",
    "url": "https://finnhub.io/api/news?id=5b36a74d200ab2b1a4a97f9bdf0c2793c7b78086429a77897cbf53cd56115c60",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751459640,
      "headline": "Vertex Gets EU Nod for New Cystic Fibrosis Drug Alyftrek",
      "id": 135714211,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "VRTX secures EU approval for Alyftrek, a next-in-class triple combination regimen for treating people with CF aged six years and older.",
      "url": "https://finnhub.io/api/news?id=5b36a74d200ab2b1a4a97f9bdf0c2793c7b78086429a77897cbf53cd56115c60"
    }
  },
  {
    "ts": null,
    "headline": "Vertex wins European approval for Alyftrek, bolstering cystic fibrosis stronghold",
    "summary": "With its blockbuster Trikafta set to lose patent protection within the decade, Vertex is strengthening its cystic fibrosis portfolio.",
    "url": "https://finnhub.io/api/news?id=4f370d3d470d42c37c1831fcc220914484407520f5ae5be5e76714031c6136bf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751454481,
      "headline": "Vertex wins European approval for Alyftrek, bolstering cystic fibrosis stronghold",
      "id": 135711295,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "With its blockbuster Trikafta set to lose patent protection within the decade, Vertex is strengthening its cystic fibrosis portfolio.",
      "url": "https://finnhub.io/api/news?id=4f370d3d470d42c37c1831fcc220914484407520f5ae5be5e76714031c6136bf"
    }
  }
]